Drug intelligence / Profile preview

Huayu Sanjie Pian

Development stage: Unknown
Lead developer: Xi’an Beilin Pharmaceutical
Administration: Oral

Overview

Huayu Sanjie Pian is a Traditional Chinese Medicine (TCM) tablet developed by Xi'an Beilin Pharmaceutical. It is primarily investigated for the treatment of proliferative vitreoretinopathy (PVR) following surgery for rhegmatogenous retinal detachment (RRD). In TCM theory, the formulation is designed to treat the 'phlegm and blood stasis' syndrome, which is associated with the pathological proliferation of cells and extracellular matrix in the vitreous cavity and on the retinal surfaces. By resolving stasis and dissipating nodules, the treatment aims to improve surgical outcomes and prevent vision loss associated with PVR-induced retinal traction.

Brand names: Huayu Sanjie Pian
Other names: 化瘀散结片

Targets

TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on Huayu Sanjie Pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huayu Sanjie Pian.

Explore the full profile